Boris D Heifets
@TheBorisLab
Followers
3,336
Following
1,160
Media
197
Statuses
2,008
Anesthesiologist, neuroscientist, amateur psychiatrist. I know where the most powerful psychotropic drugs in the hospital are.
Stanford, CA
Joined November 2018
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
بايرن
• 524729 Tweets
موناكو
• 523341 Tweets
Wizkid
• 302438 Tweets
Davido
• 283723 Tweets
Adams
• 124243 Tweets
#BrightestStarBangChan
• 109850 Tweets
#우리의_찬란한_청춘_방찬에게
• 108676 Tweets
Doug Emhoff
• 70881 Tweets
Shakira
• 51548 Tweets
CHAE X JESBIBLE
• 45204 Tweets
Shana Tova
• 41457 Tweets
Centro Carter
• 38258 Tweets
Gago
• 35040 Tweets
KARIME EN HOY
• 34676 Tweets
Cassper
• 34104 Tweets
Rosh Hashanah
• 33218 Tweets
GALA EN HOY
• 32610 Tweets
Lille
• 25515 Tweets
センラさん
• 17156 Tweets
NASCAR
• 16640 Tweets
Girona
• 14784 Tweets
Channie
• 14631 Tweets
Bologna
• 14553 Tweets
Marburg
• 13948 Tweets
ITZY IS THE MOMENT
• 11311 Tweets
Feyenoord
• 10390 Tweets
Camavinga
• 10100 Tweets
Pinned Tweet
SPIKED: Stanford Placebo vs Intraop Ketamine Evaluated for Depression. We masked ketamine with surgical anesthesia in depressed patients. Full details now published, peer review pending. Huge antidepressant response in both groups.
@TheresaLii
1st auth
96
274
1K
Congrats
@NewYorker
for blowing my mind this beautiful Sunday morning. Had no idea psilocybin microdosing was effective, safe and legal to advertise as a therapy. Nov 27 2023 issue, right next to “How pizza became New Havens calling card”🫠The FDA is imperfect, but holy sh!t.
51
70
300
How important is psychedelic "setting" really? Can we measure psychedelic synergy? We reduced this Q to the basics: does environment alter psilocybin effects, measured as activation of cells across the entire brain? co-led by
@DanRyskamp
@aminoacidhead
16
66
242
Peer-reviewed and published today in
@NatMentHealth
Thank you co-authors, and particularly
@SNACCNeuro
for seed funding.
SPIKED: Stanford Placebo vs Intraop Ketamine Evaluated for Depression. We masked ketamine with surgical anesthesia in depressed patients. Full details now published, peer review pending. Huge antidepressant response in both groups.
@TheresaLii
1st auth
96
274
1K
18
62
239
Fortunate to have
@RCarhartHarris
talk on mechanisms of classic psychedelics for our Intro to Psychedelic Medicine course
@Stanford
! Registration capped within a few hours- can’t imagine a course like this when I was an undergrad. Looking fwd to more Bay Area collabs!
8
19
215
We are now recruiting for a study of
#psilocybin
for chronic low back pain!
screen here:
Please RT
...........................................
Close collab w
@TrPR_Program
@thebandlab
Michael Silver
@UCBerkeleyNeuro
#ChronicPain
17
63
184
Maybe a first, at least in published lit- remission of a psychiatric disorder after a dream during surgical anesthesia . Dreaming caught on EEG. Paywalled, but here are the highlights:
11
42
187
In 2018, we (w
@NolanRyWilliams
) found that an opioid antagonist, naltrexone, blocks
#ketamine
's antidepressant effect. Is ketamine an opioid? What else does naltrexone do? We took these Qs into mice to get some answers, with
@mCherryGarcia
and many more
7
60
176
I’m usually first to see confounds in our own data— but the massive placebo effect is hard to miss. And I don’t think it’s because sevoflurane and propofol are potent antidepressants at the doses we used- more detail to come as we finish analysis
21
35
149
Massively disappointing move by the FDA. Plenty of options for a conditional approval, they've done it before. Hard to ignore that a new way of approaching mental health is at stake, a + signal from the FDA would go along way to support innovation.
19
33
150
Two patients in our care stopped having nightmares about their deceased children after a prolonged dream state induced by anesthesia.
@APAPubJournals
, with
@drpuppychow
@PilleriinSikka
et al.
6
26
136
Our study on neural mechanisms behind
#MDMA
's prosocial vs reward effects is out in
@ScienceTM
!
#MDMA
may be a sea-change for tx of PTSD, but should be a starting point for therapeutic development, not an end point. Details: 1/4
3
27
106
Placebo is a therapeutic physiological process, not an artifact of clinical trials, and it's not trivial. If ketamine, or a psychedelic, or a vacation, or a near death experience can catalyze that process, I hope we learn enough about it to put it to use in the clinic everyday.
6
12
94
maybe it is?? What does that say about the importance of receptors mechanism vs the value of positive expectation, a big central event (our pts had the scars to prove it, even if unconscious), and trusting your safety to a team whose sole job is to watch over you? More to come!
9
1
94
A cpl weeks ago we wrapped our 3rd year of PSYC 215 Intro to Psychedelic Medicine, led by Patricia Suppes, Gianni Glick & me - great student response, thoughtful discussion and some fantastic guest lectures! Sharing some of the lectures for those interested:
4
18
81
In psychedelic science, some see “its placebo” as an attack. I embrace placebo (well done placebo!) as a mechanism of action - a process which psychedelics tx can powerfully engage. This study on *open label placebo* from an outstanding group speaks volumes to that idea. 👏👏👏
Delighted to share our latest: the effects of an *open-label* placebo injection on clinical outcomes & brain function in chronic back pain
we gave participants a placebo (saline) subcutaneous injection -- and we told them it was a placebo
1/n
8
35
105
15
7
82
Anthropological Research Reveals Ancient Cultures Used Psychedelics To Increase Productivity Within Startup Companies via
@theonion
3
11
78
Pretty wild case report, non-psychedelic psilocybin dose is still effective for depression ... N=1 ofc. I'd talk smack but we cured PTSD in N=1 with just a little propofol and a dream.
Non-drug factors likely key here...
Very interesting case lead by Dr Josh Rosenblat from our team that the use of a 5HTA antagonist with psilocybin did not attenuate antidepressant effect in TRD raises interesting conceptual questions on mechanisms of psilocybin effects .
7
35
118
5
15
77
We're developing a questionnaire to learn more about people’s exposure to media related to psychedelics. No need for direct psychedelic experience. 5-10 min. If you would like to participate in this study, please follow this link: 1/2
10
42
70
Sasha’s spirit lives on at the Alexander Shulgin Research Institute!
5
7
78
This is important. MDMA has enormous potential… but any potent therapy by definition carries risk. Allegations of trial misconduct are serious and the FDA should, at the least, allow a public hearing. We can’t manage risks we don’t understand.
Informed by new evidence of systematic data fraud at MAPS PBC, we wrote a petition calling for the FDA to schedule an open advisory committee meeting on Lykos’ application for MDMA-assisted therapy that prioritizes contributions from all stakeholders: /1
16
39
97
4
19
66
Several limitations. Is ketamine all expectancy? Probably not. We weren't expecting this result. I wish we'd have measured expectancy before treatment!
Did anesthesia block an effect of ketamine? Maybe, but..
@Ryan_ETyler
could be, but possibly “blocking” in this trial gives the same effect size as most ketamine trials in awake patients - have to conclude that an “unblocked” ketamine effect would be significantly >~60% response rate. I was more surprised by the placebo effect size!
2
1
9
4
2
68
Know someone with back pain?
We're recruiting for a study of
#psilocybin
for chronic low back pain!
screen:
Please RT
...........................................
Close collab w
@TrPR_Program
@thebandlab
Michael Silver
@UCBerkeleyNeuro
#ChronicPain
5
31
68
I think it’s the other way around- mouse models of ketamine have made many testable predictions in humans, virtually all of which have failed. So do we bend our understanding of humans to fit mouse data, or find a new mouse model? 🧵
@TheBorisLab
@PloederlM
Clearly there are still many questions, but the results of the experiment in mice should be accounted for in the analysis, right?
3
0
1
8
11
67
My dept
@stanfordanes
is recruiting faculty! We are particularly looking for neuroscientists (!!)- anesthesia is a big academic space with huge room to grow. Stanford has world class neuroscience, and I would love to see our dept grow in that direction.
0
18
63
Is general anesthesia an antidepressant? We avoided N2O , tho 3/40 did get it. We used propofol and volatile anesthetic at much lower doses (EEGmonitored) than used in antidepressant studies of those compounds, e.g. ....and....
4
7
65
Congrats
@dr_brein
@MoeNeuro
et al. Glad to have contributed! MDMA enhances social transfer of affective states - something we intuit in humans, and we now have a candidate mechanism for in mice— more to come!
Thrilled to share that my postdoc work from the Malenka lab is out today!
Of course, this work will not be complete until it’s communicated. Short video summary coming soon
6
36
147
1
9
58
Wonderful visit from the godmother of
#ketamine
(among many other contributions to neuroscience!). thanks
@LeiliMortazavi
@StanfordBrain
for making it all happen
@knutson_brain
@bita137
@CRodriguezMDPhD
And thank you to
@CRodriguezMDPhD
and
@TheBorisLab
for enlightening discussions about ketamine among other timely topics 😊
0
2
22
2
5
55
Our review on Hallucinogens in Mental Health, covering preclinical & clinical
#LSD
,
#psilocybin
,
#MDMA
&
#ketamine
research out now
#JNeurosci
@SfNJournals
! Big thx to Danilo de Gregorio & Gabriella Gobbi, & coauthors including
@ArgelAV
@KatrinPreller
1
14
57
Many examples of psychedelic-like experiences induced by a range of drugs and non-drug techniques. Surprising overlaps in physiology, phenomenology and lasting therapeutic effects - IMO creating and shaping an experience deserves far more focus than receptor biology
3
7
55
Our take on
#psychedelics
& expectancy with the brilliant
@psybalazs
. Great expectations & hope are as powerful as a drug - so why not treat them that way in trials? Expectancy has a mechanism, and may have more in common with psychedelics that we think!
#Psychedelics
are interesting. Expectancy effects are cool. So why not write a review of "Expectancy effects in psychedelics" with
@TheBorisLab
?!?
👉
2
10
51
6
11
55
Antidepressant response rates similar, >50% in both groups. Remission rates 35-50%. Comparable to high quality previous studies
2
3
54
Patients received ket or normal saline at standard EEG-defined depth of anesthesia. At the end of the trial we asked what treatment arm they thought they were in:
2
2
54
Moving to something less controversial than MDMA for a minute - *consciousness*! Join us in Tuscany, Italy Jan 26-31, 2025 for a Gordon Research Conference on Consciousness, Anesthesia & Evolutionary Biology. Incredible speaker lineup.
3
12
54
Loved writing this with
@DEOlsonLab
- we have some differing views on psychedelics! Thx
@npp_journal
for giving us the space to explore Qs like how to model the complexity of psychedelic therapy in lab species- more to come!
New review now online - part of
@npp_journal
reviews 2024 issue
#NPPR2024
from Boris Heifets
@TheBorisLab
and David Olson
@DEOlsonLab
, "Therapeutic mechanisms of psychedelics and entactogens"
0
18
56
1
14
52
What happens after you walk into a ketamine clinic? We analyzed outcomes of ketamine therapy for depression from 178 clinics in 40 states, , using
@OsmindHQ
e-health record software - great collab including Alison McInnes,
@JimmyJQian
et al. 🧵 1/
2
15
50
Thanks you Nina Bai
@StanfordMed
for the writeup of our study! out today in
@NatMentHealth
"Randomized trial of ketamine masked by surgical anesthesia in patients with depression"
3
10
48
Depression & mental health issues can worsen after major trauma, including surgery. We screened 3000 people coming for surgery
@StanfordMed
for
#depression
to understand the extent of the problem. Just out in
@BJAJournals
, 1st auth
@TuuliHietamies
8
12
50
I have a lot of respect for the authors, but I agree w
@PloederlM
- glutamate is the most widespread excitatory neurotransmitter in the brain, present… everywhere. Of course it’s involved in everything. “Targeting” it doesn’t seem to work well- their own figure sums it up!
Are you in need of a new chemical imbalance theory if depression? Here you go:
7
21
63
6
7
47
We should expect risk for MDMA-assisted psychotherapy….it’s a major intervention proportional to the severity and mortality of severe PTSD. And like in any other field of medicine, we can’t mitigate risk if we haven’t measured and reported it.
"I would really like to understand the risk profile of this drug before it's approved, not after."
-
@TheBorisLab
2
5
25
4
10
46
Very grateful to our two patients who were willing to share their profound experiences of reunion while dreaming during anesthetic emergence. Thank you
@drpuppychow
et al for editing -
Two patients in our care stopped having nightmares about their deceased children after a prolonged dream state induced by anesthesia.
@APAPubJournals
, with
@drpuppychow
@PilleriinSikka
et al.
6
26
136
2
13
44
Faculty hiring! Please RT - my dept
@stanfordanes
is recruiting a basic/translational neuroscientist, open rank. Looking forward to deepening the link between anesthesia & neuroscience at Stanford
1
24
43
#MDMA
or a 5HT-1b agonist improves social deficits in 4 different mouse autism models. Love being part of this team - congrats
@LabWalsh
@DoctorDanPhD
@dcardozopinto
, Rob Malenka, et al. One of these days we'll figure out how to model mouse psychotherapy too.
Excited to share this story and for what the future holds!
@UNC_PHCO
@DoctorDanPhD
@UNC_CBP
@StanfordBrain
@TheBorisLab
1
8
34
0
8
43
Here’s another prediction: data will show you don’t even the psychedelic drug to benefit from psychedelics. Actually scratch that, data is already here. Quality psychoherapy is incredibly powerful and undervalued.
Prediction: over the next few years, data will show that (in most cases) you don't actually need therapy to benefit from psychedelics
62
22
255
9
5
41
Hey we made a list of superlatives!!! I’d like to thank the Stanford IRB for falling asleep at the wheel and approving our study, and our many colleagues, journal reviewers and funding agencies for politely nodding and smiling while we carried on 🤩
@DKThomp
@TheBorisLab
ahoy
@DKThomp
. i’m a fan, but this was one of the worst studies i’ve ever seen in psychedelic sciences. No worthwhile practitioner claims psychedelics work without therapy or mindfulness. This conclusion doesn’t represent how psychedelics work in the field
3
0
1
4
5
41
Love the opportunity to update
#SNACC21
on our work woth depressed patients coming through the Stanford ORs! Huge thx to
@SNACCNeuro
for the award- inspiring to get a “yes” in a sea of “no”s as a new(ish) PI
Congratulations Dr. Boris Heifetz on the 2019 William L. Young Research Award
@stanfordanes
Ketamine Therapy for Reducing Perioperative Risk in Depressed Patients
#SNACC2021
!
Make sure you
#SNACCpledge
to this research fund to support future
#neuroanesthesia
research like this👍
1
6
24
6
2
40
Thank you Nina Bai
@StanfordMed
for this beautiful writeup detailing the story of our patient who, after an experience under anesthesia, found peace after the loss of her son. Nice perspectives from the team as well
@drpuppychow
@PilleriinSikka
3
8
39
Great teamwork on this deep look at human circuits! Thx to lead author
@DanBarbosa39
and senior
@CaseyHalpern5
. More to come!
FINALLY published in
@Nature
! Amazing team effort allowed pushing human brain circuit-based investigations to the next level!
@gattas_sandra
@jms_salgado
@allanrw_
@YuhaoHuangMD
@dora_hermes
@Kai_J_Miller
@TheBorisLab
@CaraBohon
@jennifer_mcnab
@halpernc
5
12
64
1
5
39
In 1965, Domino wrote about "Taming the ketamine tiger". Maybe more like an octopus? Tentacles in every corner of medicine! Thanks to
@_Anesthesiology
for letting me make this analogy in print . Comment on
3
9
37
1
4
36
Our preprint is out! MDMA ('ecstasy') + psychotherapy has major promise for treating severe PTSD -in phase 3 trials. It also has abuse/misuse potential that may complicate treating millions of patients. Can we separate these facets for safer therapy? 1/8
4
17
35
Thank to
@VineVentures
for sponsoring this forum at
#SXSW
! Great chat w
@RCarhartHarris
and
@z1awrence
, speculating broadly on the future of the psychedelic industry
.
@TheBorisLab
"Grouping of psychedelics as one broad category is more a sociological convention than one based on a scientific approach. What separates this class of compounds is that we can trigger changes that remain long after the psychedelic effects have worn off"
#SXSW
0
2
17
3
6
36
Very well considered comments on the strengths and limitations of today’s psilocybin vs SSRI trial in NEJM from
@RCarhartHarris
et al. The inconclusive outcome may say more about a generation of psychiatric scales designed for SSRIs then it does about psychedelic potential
expert reaction to phase 2 trial comparing psilocybin and escitalopram for depression | Science Media Centre
3
39
142
2
7
36
Over the years I’ve heard some amazing stories from patients about transformational experiences linked to standard anesthetics— seems clear the potential is there and worth exploring. Thank you
@shayla__love
for a beautiful piece.
I wrote about people who had dream-like experiences when coming out of anesthesia, and said these dreams reduced their trauma symptoms.
Intriguing case studies from
@TheBorisLab
,
@drpuppychow
,
@PilleriinSikka
, and more at Stanford.
2
16
39
4
5
35
Group therapy + psilocybin . Pioneering work led by Brian Anderson & Josh Woolley
@thebandlab
. First published study I know of - love the idea of pods of patients bound by this experience, maintaining therapeutic bonds as a community. Done v well here.
1
9
35
Great fun talking last week with one of the most science literate and curious hosts
@trikomes
. Got me thinking more about the boundaries between sleep and anesthesia, and some of the subtle diffs in what conscious experience is like in these disconnected states 💭💭💭
New podcast episode:
"Anesthesia, Placebo Effects, Consciousness, Subjectivity, MDMA, Ketamine, Opioids, Psychedelics"
With anesthesiologist Dr. Boris Heifets (
@TheBorisLab
).
Link in bio.
2
5
30
2
6
33
R-ketamine in humans, open label. Big effect, "dissociation was nearly absent". More evidence separating the subjective experience of ketamine from its persistent antidepressant effect.
3
11
31
@therealbrom
Yes, eventually the market (and data produced in its service) will devalue human connection for the sake of a scalable commodity. Prediction: it will suck
1
0
32
$CMPS released topline results from their phase 2b psilocybin for depression trial- well powered, largest of its kind, and (formally) the first positive placebo controlled randomized trial of psilocybin for tx resistant depression
2
10
30
Come for the science, stay for the drama!
Starting now
#NPPR2024
panel on Rapid and Novel Treatments in Psychiatry
@ACNPorg
w amazing line up
@LisaMonteggia
@jmaglab
@AlikWidge
@TheBorisLab
⭐️
#ACNP2023
w co-chair Chuck Zorumski (attending virtually)
@npp_journal
👇👇👇
1
10
36
3
5
31
@LeorRoseman
@REMAPTherapy
@TheresaLii
some might take away that we could dispense with the drug altogether and keep the therapy...but having a focal event may be important... like every ritual ever!
@JeeshanJourney
@TheresaLii
These data can't say. IMO, suggests that the structure of the intervention - prep, trust, "big event" (even if a memory hole), after-care - these are so important, possibly moreso than the specific drug used. Our pts did have an experience - just not one usu assoc w psychedelics
1
1
21
1
0
30
Not in the preprint: we re-analyzed data based on patients' guesses on Day 14. If they felt better, they tended to guess they got ketamine. This is strong encouragement for us to measure and control for expectancy in future studies
5
3
30
I am mystified that this is coming up now after 1) spravato and 2) the FDA signed off on the trial design?? Wasn’t that the point of breakthrough therapy status?
Would like to see that followed that up with:
"If these trials are, for all intents and purposes, open-label, considering the fact that FDA is legally bound to require efficacy trials that are 'adequate and well-controlled', should we even be holding this meeting?"
2
1
9
5
1
27
Seen by Dr Hack & now Dr Makoto Kawai (
@Stanford_Neuro
, sleep specialist). Near total resolution of acute stress disorder & nightmares...from postop day 1 through 6 months out. we think we know what to look for now...case series in progress
2
1
28
Your daily reminder that powerful life altering experiences aren’t always therapeutic. The “plasticity” doesn’t necessarily know it’s supposed to be helping you
A promising field
But a cautionary tale
Hot Take: Psilocybin was the Biggest Mistake of My Life
783
361
3K
5
0
28
aaaand MDMA stays on schedule 1... research continues to be slow, painful and a regulatory pain in the 🫏
0
0
27
Ultimately yes, the FDA was justified in rejecting MDMA based on Lykos data - this is an important take below. Yet, almost certainly could have found some middle ground, as in the past. Drug assisted psychotherapy is likely to be an important and impactful approach, but ?now DOA
The FDA decision on Lykos' MDMA application is bittersweet at best, especially for those who do need treatment for treatment resistant PTSD. The decision is also entirely justified and I believe the right one.
Rick Doblin and MAPS openly treated the FDA process with so much
11
34
126
2
2
27
Pre-pub data from our group at
#sfn2022
- brain wide imaging of
#ketamine
,
#psilocybin
and
#mdma
in mice, pinning down mechanism for a range of behavioral effects. Tues AM, 483.01-07, QQ and RR and Mon AM minisymposium
0
4
27
a privilege to have pain experts like
@TawfikLab
and
@Vafisalmasi
on board with this trial! I’ve been working closely with
@thebandlab
and Michael Silver at UC Berkeley for > 1year developing the protocol to study psilocybin for chronic pain. Looking forward to a 2021 start!
Stanford researchers Vivianne Tawfik (
@TawfikLab
) and Boris Heifets (
@TheBorisLab
) are exploring the use of psychedelic drugs in pain management.
3
13
48
0
1
25
Finally, a word about placebos. This study does not show that ketamine is "just a placebo". I'm quoting a paper from *1957* (Gliedman et al Am J Psych) who say better than I can:
1
2
26
RIP Steve Albini, amazing musician, engineer, analog zealot and contributing author to the soundtrack of my youth
I certainly have some 'splainin to do, and am not shy about any of it. A lot of things I said and did from an ignorant position of comfort and privilege are clearly awful and I regret them. It's nobody's obligation to overlook that, and I do feel an obligation to redeem myself...
9
68
2K
1
2
26
Nitrous as an antidepressant! Great to see this successful phase 2,
@nagelep1
@BenPalanca
et al.
#Anesthesiology
truly developing as a field of applied clinical
#neuroscience
, and blurring traditional disciplinary bounds 1/
1
8
25
My wild take: good tx on psilocybin is the sum of good tx + whatever psilo does. You can access that magic in a therapy suite, in nature, at a rave - setting plays the same role as in the rest of life. Thx coauths, on&off twitter!
@TuuliHietamies
@mCherryGarcia
@CaseyHalpern5
2
0
26
This study of beliefs shaped by psychedelic came from an awesome collaborative team - Huge thanks to
@audreygevers
Chris Kelly
@shayla__love
@TehseenNoorani
for developing it, and many others for valuable input. Please share the survey below, looking fwd to posting results
We're developing a questionnaire to learn more about people’s exposure to media related to psychedelics. No need for direct psychedelic experience. 5-10 min. If you would like to participate in this study, please follow this link: 1/2
10
42
70
1
7
24
Great working with you all on this! Tip of the iceberg re DA and 5HT interactions in the NAc. My fave, ofc, is
#MDMA
vs methamphetamine - MDMA seems to "tune out" mPFC, METH seems to "tune in" to PVT. Stay... tuned
Excited to share our latest work, with
@LabWalsh
,
@TheBorisLab
, Paul Hoerbelt from the Malenka lab
@StanfordBrain
@StanfordPSY
! … my 2nd of 2021!
3
5
34
2
0
24
Thanks to
@Stanford_PMHW
for hosting- it’s been huge, fascinating fun scanning people on ketamine and MDMA! Moving ever closer to aligning mouse and human brain dynamics 💪🤩
🎧Check out PMHW's newly released 'Chat with the Experts' Ep.1 with Drs. Boris Heifets (
@TheBorisLab
) and Laura Hack - 'Science at the border of anesthesia and psychiatry' - Use of psychedelics in the treatment of mental health disorders.
Visit:
0
2
5
2
3
24
Public workshop today on the changing landscape of ketamine use - put on by the FDA and
@reaganudall
- including a panel on online promotion of ketamine for [checks notes] everything. Increased access to care 👍, but care is more than providing a drug
1
3
24
Migraine suppressed for 2 weeks after a single dose of psilocybin. Treatment effect uncorrelated to psychedelic effect... neurovascular effect of 5HT2a agonists different from cortical? wouldn't be a shock. looking forward to seeing more from Emanuelle Schindler et al!
New
#psychedelic
trial: Small, well designed proof-of-concept study out of
@NeurologyYale
demonstrating a single administration of low-dose
#psilocybin
decreases the number of weekly migraine days over a 2-week period compared to placebo.
3
15
53
2
6
24
@npp_journal
Thank you
@npp_journal
and reviewers for one of the easiest publishing experiences I’ve ever had! Review substantially improved the study. Thx co 1st auths,
@DanRijsketic
@aminoacidhead
, and coauthor
@LMWilliams_PhD
@warmxue
@TuuliHietamies
et al et al
5
6
24
What does it mean? naltrexone is not a silent manipulation that's inert until ketamine shows up. We think the endogenous opioid system, with a hub in the central amygdala, is controlling other brain areas where ketamine acts more directly, perhaps via NMDARs. Testable in humans!
4
0
23
Our analysis of ketamine vs ket + naltrexone in suicidality - ket’s effect on suicidality and depression may differ, but both opioid receptor dependent. Thx to my co-1st
@NolanRyWilliams
for roping me in a few years ago!
1
10
22
@JeeshanJourney
@TheresaLii
These data can't say. IMO, suggests that the structure of the intervention - prep, trust, "big event" (even if a memory hole), after-care - these are so important, possibly moreso than the specific drug used. Our pts did have an experience - just not one usu assoc w psychedelics
1
1
21
@richardludlow
@TheresaLii
There is some data... pts recruited for a delirium trial , mood outcome collected as well. Pts w pre-existing depression got worse. caveats abound, but in general we did not expect to see the observed degree of improvement. Supports an expectancy effect IMO
0
0
22
Thank you
@SNACCNeuro
for the William Young L Young Neuroscience Research Award! Great meeting in Phoenix, looking forward to next year in Montreal
3
1
22
We're not ready to abandon the RCT gold standard quite yet for psychedelics! Loved brainstorming and writing w
@JacobSAday
@thebandlab
et al - we review the most innovative ideas in psychedelics' trial design and offer a few of our own. Free:
Our review article on the challenges of conducting psychedelic clinical trials and how to improve methodology is now available online: 🧵👇
3
29
92
1
1
22
Nice summary of the massively hyped $CMPS phase 2b study psilocybin for TRD - thanks
@Josh__Hardman
and
@PsilocybinAlpha
for including my comments!
🔖 Special Issue: 2b, or not to be?
Preparing for COMPASS Pathways’ Data Readout
In this special issue we explore the significance of these forthcoming $CMPS results and aim to provide a primer on their interpretation.
2
8
24
0
3
20
Many miles to go before we abandon hope of placebo controlled RCTs for psychedelics, still the gold standard for informing medical treatment. A pleasure writing this with you
@JacobSAday
,
@thebandlab
et al! As ever building on the work of giants who pioneered the field.
@TrPR_Program
is excited to share a new preprint article titled "Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials" 🧵👇
3
11
55
2
4
19
If there are compelling arguments to be made… this is probably the place to hear them
Do psychedelic medical treatments always require psychotherapy? A debate / discussion with Compass Pathways' Professor Guy Goodwin (who thinks not) and Open Foundation's Dr Max Wolff (who thinks so). December 11, 6pm GMT, online, free.
18
21
99
2
3
19
More evidence for a ketamine / opioid receptor interaction, ft the ?possibly antidepressant metabolite 2R6R-HNK, from Tom Joseph et al
@PennAnesthesia
. Molecular dynamics and in vitro... still plenty of questions
3
4
20
Ketamine loss and return of consciousness - beautiful ephys in nonhuman primates... nb the evolving high frequency oscillations. "It is possible that these animals...were continuously conscious internally after loss of responsiveness"
1
4
18
4
0
20
Non-hallucinogenic derivative of the
#psychedelic
ibogaine with therapeutic potential - congrats to the Olson lab & collaborators. My (safe) bet: removing the "psychedelic"-ness will diminish but not eliminate efficacy. Looking fwd to seeing this tested in humans!
Check out our paper in
@nature
describing TBG, a non-hallucinogenic, non-cardiotoxic
#psychedelic
analog with therapeutic potential. Great collaboration with
@MileHighLab
,
@ron_dorit
,
@lein_lab_ucd
,
@WCMC_UCDavis
, and others!
11
63
265
3
2
20
@stanfordmed
residents are high risk frontline workers, I hope you take action to fix this NOW! Personally I can wait on the vax, I’m in the OR a day a week. Our residents are the ones getting exposed every day
2
4
19
Such a maddeningly empty press release for such an interesting question…
@atai_life
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Ph 1 Study with EMP-01 (R-MDMA)
"We found differences in the subjective experience R-MDMA in comparison to published reports involving racemic MDMA." - Florian Brand, CEO
2
6
27
1
2
19